Skip to content
DataLookout
Menu

NCT04759586

Nivolumab in Combination With Chemo-Immunotherapy for the Treatment of Newly Diagnosed Primary Mediastinal B-Cell Lymphoma

StatusActive, Not Recruiting
PhasePhase 3
Primary completion (estimated)

At risk: Primary completion moved at least 6 months later.

Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

The 50 most recent of 485 versions: 17 with changes below, 33 re-verified with no change. See every version on ClinicalTrials.gov ↗

  1. Notable Primary and study completion pushed from Dec 31, 2026 to Jun 30, 2027
    • Site details revised at 1 of 233 sites
  2. Notable Eligibility criteria shortened, about 50 words
    • Study description revised
    • Study sites revised (233)
  3. Minor Study sites revised (233)v480
  4. Minor Study sites revised (233)v478
  5. Minor Study sites revised (233)v476
Show 12 earlier versionsHide 12 earlier versions
  1. Minor Study sites revised (233)v452
  2. Minor Study sites: 234 to 233v451
  3. Study Status, Study Description, Eligibilityv447
  4. Notable Primary and study completion dates: Dec 31, 2027 to Dec 31, 2026v446
  5. Minor Study sites revised (234)v445
  6. Minor Study sites revised (234)v444
  7. Minor Trial status: Recruiting to Active, Not Recruiting
    • Site details revised at 234 of 234 sites
    v442
  8. Minor Site details revised at 3 of 234 sitesv440
  9. Minor Site details revised at 3 of 234 sitesv439
  10. Minor Site details revised at 1 of 234 sitesv438
  11. Minor Site details revised at 1 of 234 sitesv437
  12. Minor Site details revised at 1 of 234 sitesv436
  • Notable: the plan changed
  • Minor: routine updates

Endpoints

Primary

Progression-free survival (PFS)
Timeframe: From enrollment on the study to first occurrence of relapse/progression or death, assessed up to 7 years

Secondary (4)

Efficacy-related event-free survival
Therapy-related event-free survival
Overall survival
Proportion of positive positron emission tomography (PET) scans

Arms and interventions

Arm A (DA-EPOCH-R)Active comparator

See Detailed Description

Arm B (DA-EPOCH-R, nivolumab)Experimental

Patients receive treatment as in Arm A. Patients also receive nivolumab IV over 30 minutes on day 1. Treatment repeats every 21 days for up to 6 cycles (5 if the patient had 1 prior cycle of treatment) in the absence of disease progression or unacceptable toxicity. Patients undergo ECHO and LP for CSF collection during screening. Patients undergo ECHO during screening and as clinically indicated and LP for CSF collection optionally during screening. Patients also undergo CT or PET/CT throughout the trial. Additionally, patients undergo bone marrow biopsy and aspiration optionally during screening and as clinically indicated on study. Patients undergo blood sample collection on study.

Arm C (R-CHOP)Active comparator

Patients receive prednisone or prednisolone PO QD on days 1-5 and rituximab IV or rituximab and hyaluronidase human SC over 5 minutes on day 1 or 5. Patients also receive cyclophosphamide IV over 30-60 minutes, doxorubicin hydrochloride IV over 1-15 minutes or up to 60 minutes, and vincristine sulfate IV over 1 or up to 60 minutes on day 1. Treatment repeats every 21 days for up to 6 cycles (5 if the patient had 1 prior cycle of treatment) in the absence of disease progression or unacceptable toxicity. Patients undergo ECHO during screening and as clinically indicated and LP for CSF collection optionally during screening. Patients also undergo CT or PET/CT throughout the trial. Additionally, patients undergo bone marrow biopsy and aspiration optionally during screening and as clinically indicated on study. Patients undergo blood sample collection on study.

Arm D (R-CHOP, nivolumab)Experimental

Patients receive treatment as in Arm C. Patients also receive nivolumab IV over 30 minutes on day 1. Treatment repeats every 21 days for up to 6 cycles (5 if the patient had 1 prior cycle of treatment) in the absence of disease progression or unacceptable toxicity. Patients undergo ECHO during screening and as clinically indicated and LP for CSF collection optionally during screening. Patients also undergo CT or PET/CT throughout the trial. Additionally, patients undergo bone marrow biopsy and aspiration optionally during screening and as clinically indicated on study. Patients undergo blood sample collection on study.

Arm E (R-CHOP, radiation therapy)Active comparator

Patients receive treatment as in Arm C. Within 6-8 weeks after completion of chemotherapy, patients undergo radiation therapy over 25 fractions. Patients undergo ECHO during screening and as clinically indicated and LP for CSF collection optionally during screening. Patients also undergo CT or PET/CT throughout the trial. Additionally, patients undergo bone marrow biopsy and aspiration optionally during screening and as clinically indicated on study. Patients undergo blood sample collection on study.

Arm F (R-CHOP, nivolumab, radiation therapy)Experimental

Patients receive treatment as in Arm D. Within 6-8 weeks after completion of chemotherapy, patients undergo radiation therapy over 25 fractions. Patients undergo ECHO during screening and as clinically indicated and LP for CSF collection optionally during screening. Patients also undergo CT or PET/CT throughout the trial. Additionally, patients undergo bone marrow biopsy and aspiration optionally during screening and as clinically indicated on study. Patients undergo blood sample collection on study.

Procedures: Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy, Computed Tomography, Echocardiography Test, Lumbar Puncture, Positron Emission Tomography

Drugs: Cyclophosphamide, Doxorubicin Hydrochloride, Etoposide Phosphate, Prednisolone, Prednisone, Vincristine Sulfate

Biologicals: Filgrastim, Nivolumab, Pegfilgrastim, Rituximab, Rituximab and Hyaluronidase Human

Radiation: Radiation Therapy

Sites

233 sites in 4 countries

United States 215, Canada 12, Australia 5, Puerto Rico 1